NASDAQ NMS - GLOBAL MARKET · REGN

+1.27% · +$8.33 · Vol 554.7K

Market closed · last close 4:00 PM ET · price as of 16:14:35 ET

Regeneron Pharmaceuticals Inc

Biotechnology

$664.45

+ Add to watchlist

Card

Relationship Map

Veridion Score

Refresh

Score snapshot refresh in progress

Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS

HISTORY WINDOW BUILDING

AI Analysis

Sovereign

Why is REGN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move REGN next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Form 4 / Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Jul 15
Score
Score moved +16
49/NEUTRAL -> 65/BUY BIAS
Veridion score historySource
Jul 7
Form 4Sovereign
RYAN ARTHUR F Form 4 sale
Disclosure detail is available inside Sovereign and Reserve.
SEC Form 4Unlock receipt
Jul 6
CongressSovereign
Ro Khanna purchase disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Jul 6
CongressSovereign
Ro Khanna sale disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Jun 9
CongressSovereign
Ro Khanna sale disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Jun 8
CongressSovereign
Gilbert Cisneros sale disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Jun 8
CongressSovereign
Gilbert Cisneros sale disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
May 4
Form 4Sovereign
RYAN ARTHUR F Form 4 sale
Disclosure detail is available inside Sovereign and Reserve.
SEC Form 4Unlock receipt
Apr 3
Form 4Sovereign
RYAN ARTHUR F Form 4 sale
Disclosure detail is available inside Sovereign and Reserve.
SEC Form 4Unlock receipt

Catalyst calendar

Dated receipts for REGN are being assembled.

About Regeneron Pharmaceuticals Inc

PHARMACEUTICAL PREPARATIONS

Listed since

1991

Employees

15K

Country

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$656.11

Day high

$669.10

Day low

$648.66

Previous close

$656.12

52W high

$669.10

-0.69% from high

52W low

$648.66

77% of range

Market cap

$68.8B

P/E

16.43×

EPS

$40.45

Shares out

104.8M

Volume

554.7K

VWAP

$663.06

Price history computed in-house

-0.01%

SMA 50 $661.68 · above

SMA 200 $661.68 · above

52W position 77%

Veridion warehouse edge

Warehouse intelligence for REGN.

Veridion Score

0: 741: 462: 423: 584: 745: 70

Congress 30d

Ro Khanna · Purchase

Insider activity

See Form 4 panel below.

13F holders

None on file

Capital Web snapshots checked.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.

Related public evidence

Relationship mapTrace receipt-backed holders and filings around REGN.Congress disclosuresOpen receipt and filing context for REGN.MethodologyReview score inputs, coverage rules, and limitations.

Data ledger

Quote and day range

Refresh interval: 30 seconds

Source: Market data

Veridion Score

Coverage building

Source: Veridion methodology

Chart and risk context

Daily bars with no missing-bar fill

Source: Market data

News and filings

Refresh intervals shown inside each panel

Source: Market news and federal filings

Financials

Statements refresh in progress

SEC Form 4 ledger

REGN insider activity

Regeneron Pharmaceuticals Inc

Score

Coverage building

Pressure

Net selling

Filings

Buys / sells

0 / 22

Net value

-$278K

Insiders

Named filers

RYAN ARTHUR F

Director

Board

Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net selling: -$278K across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing date	Trade date	Insider	Title	Type	Price	Qty	Owned	Value	Receipt
2026-07-07	2026-07-02	RYAN ARTHUR F	Director	sell	$650.15	200	17,303	$130K	SEC Form 4
2026-05-04	2026-05-01	RYAN ARTHUR F	Director	sell	$703.46	24	17,559	$17K	SEC Form 4
2026-05-04	2026-05-01	RYAN ARTHUR F	Director	sell	$704.28	15	17,544	$11K	SEC Form 4
2026-05-04	2026-05-01	RYAN ARTHUR F	Director	sell	$702.46	15	17,583	$11K	SEC Form 4
2026-05-04	2026-05-01	RYAN ARTHUR F	Director	sell	$705.56	14	17,530	$10K	SEC Form 4

Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 17 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology

Congress · 90D

Congress filing snapshot refresh in progress

Federal contracts

REGN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed

Refresh interval: 12hSource: Federal contract awards

No federal contracts on file for REGN in this window.

Lobbying spend

REGN lobbying filings, year to date.

Registered lobbying filings matched to Regeneron Pharmaceuticals Inc.

$1.5M

Refresh interval: 12hSource: LDA disclosure filings

Health IssuesHealth Issues Medicare/Medicaid Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue CodeTaxation/Internal Revenue Code Health Issues Medicare/Medicaid Copyright/Patent/Trademark Trade (domestic/foreign)

Filing

$640.0K

REGENERON PHARMACEUTICALS INC

REGENERON PHARMACEUTICALS, INC

Apr 20, 2026

Filing

$610.0K

REGENERON PHARMACEUTICALS INC

REGENERON PHARMACEUTICALS, INC

Jan 20, 2026

Filing

$90.0K